Search the Newsreel

Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX

Quantinno Capital Management LP significantly increased its stake in Celldex Therapeutics (NASDAQ:CLDX) by 178.7% in the first quarter, purchasing an additional 42,158 shares to own a total of 65,744 shares valued at $2.09 million. This move comes as institutional investors continue to adjust their …

E. Ohman J or Asset Management AB Has $7.62 Million Position in DexCom, Inc. $DXCM

E. Ohman J or Asset Management AB increased its stake in DexCom, Inc. by 18.9% in the second quarter, bringing its total holdings to 113,204 shares valued at $7.62 million. Other institutional investors also adjusted their positions in the medical device company. Insider activity …

Alliance Private Wealth LLC Has $830,000 Stock Position in FedEx Corporation $FDX

Alliance Private Wealth LLC has reduced its stake in FedEx Corporation by 55.6% during the second quarter, bringing their total holdings to 2,650 shares valued at $830,000. Despite this, several other institutional investors increased their positions in FedEx. Analyst ratings show a "Moderate Buy" …

Projeções de Resultados: Dexcom Inc (DXCM) — LPA e Crescimento de Receita

Is FedEx (FDX) Using Robotics To Sharpen Its Cost Edge Or Just Keep Pace With Rivals?

FedEx has already begun deploying Dexterity's dual-armed Mech trailer loading robots at its Hagerstown, Maryland hub, automating physically demanding trailer-loading tasks to enhance efficiency in its ground operations. This move underlines FedEx's push to embed advanced robotics into its network, aligning its automation efforts …

Unos resultados más sólidos en el segundo trimestre y unas perspectivas más optimistas para 2026 podrían cambiar los argumentos a favor de invertir en DexCom (DXCM)

Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom (DXCM)

DexCom (DXCM) reported stronger-than-expected Q2 2026 results with increased sales and net income, and raised its full-year 2026 revenue guidance. This positive performance reinforces management's confidence in the demand for its continuous glucose monitoring systems and supports the adoption-driven catalyst investors are watching. Despite …

Dexus Convenience Retail REIT releases 2026 Annual Report and underscores income-focused strategy

Is FedEx (FDX) Undervalued As Trailer Loading Automation Starts At Its Hagerstown Hub?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. FedEx (FDX) has started using Dexterity's dual armed Mech trailer loading systems at its …

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

IDEXX Laboratories Inc. (IDXX) saw its stock rally by 1.55% to $595.76 on Monday, performing strongly despite an overall poor trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both experienced declines. IDEXX Laboratories Inc. is currently trading …

Addex Therapeutics Ltd (NASDAQ: ADXN) Share Price, ADXN Stock News, ADXN Share Price & Updates

FedEx Corp. stock outperforms competitors on strong trading day

FedEx Corp. (FDX) shares rose 2.04% to $325.08 on a Monday that saw overall market declines, with the S&P 500 and Dow Jones Industrial Average both falling. This marked the third consecutive day of gains for FedEx's stock.

Pro-Dex Inc (PDEX) Positioned to Strengthen with Zimmer’s mBos Robot Commercialization

Long Cast Advisers, an independent registered investment adviser, released its Q2 2026 investor letter. A copy can be downloaded here. The firm reported strong earnings in the second quarter, with results improving 20%, bringing year-to-date returns to +19%. While performance trailed the Russell 2000 …

DexCom stock hits 52-week high at 87.85 USD By Investing.com

DexCom Inc.'s stock reached a 52-week high of $87.85, reflecting strong investor confidence and market sentiment. The company reported robust second-quarter revenue, surpassing analyst estimates, and raised its guidance for the second consecutive quarter. Analysts from RBC Capital, BTIG, Canaccord, TD Cowen, and Piper …

Dexus Convenience Retail REIT (ASX:DXC) Rises As FY26 Results Support Distributions

Dexus Convenience Retail REIT (ASX:DXC) Holds Steady As Rate Anxiety Tests Income Appeal

FedEx, Amazon pursue expanded use of robotic arms

FedEx and Amazon are significantly expanding their use of robotic arms to boost productivity and reduce the physical demands on employees in their logistics networks. FedEx recently deployed Dexterity's dual-armed trailer loading systems at its Hagerstown Hub and plans to scale this technology across …

Dexus Convenience Retail REIT (ASX:DXC) Shares Carry High Payout Pressure

Contravisory Investment Management Inc. Purchases Shares of 5,194 IDEX Corporation $IEX

Contravisory Investment Management Inc. recently acquired 5,194 shares of IDEX Corporation (NYSE: IEX) during the second quarter, valued at approximately $1.18 million. IDEX exceeded quarterly earnings expectations with $2.32 EPS and $920.6 million in revenue, leading analysts to maintain a "Moderate Buy" rating and …

Will Medexus Pharmaceuticals Inc (MDP) Beat Estimates Again in Its Next Earnings Report?

Dexus Convenience Retail REIT Reports 43.2% Rise in Net Profit for Year Ended 30 June 2026

Dexus Convenience Retail REIT (ASX:DXC): Why Is Value in Focus?

Earnings call transcript: Dexus Convenience Retail REIT meets guidance in H2 2026

What's Going On With Medexus Pharmaceuticals Inc Stock Sunday?

Dexus Convenience Retail REIT: Profit up and distributions grow despite revenue dip

Dexterra Group Q2 Earnings Call Highlights

Key Points Interested in Dexterra Group Inc.? Here are five stocks we like better. Strong Q2 financial performance: Revenue rose 8% year over year to C$269 million, adjusted EBITDA increased 9% to C$33 million, and free cash flow reached C$22 million. Net debt fell …

Assenagon Asset Management S.A. Has $46.72 Million Holdings in DexCom, Inc. $DXCM

Assenagon Asset Management S.A. significantly reduced its stake in DexCom, Inc. by 59.7% in the second quarter, now holding 693,635 shares valued at $46.72 million. Despite this, institutional investors collectively own 97.75% of DXCM, and analysts generally maintain a "Moderate Buy" rating with an …

FedEx Corporation $FDX Shares Purchased by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in FedEx Corporation (FDX) by 15.9% in the second quarter, bringing its total holdings to 25,299 shares valued at approximately $7.9 million. Other institutional investors also adjusted their positions, and 84.47% of FedEx stock is now owned by institutional …

Seilern Investment Management Ltd Purchases 16,729 Shares of IDEXX Laboratories, Inc. $IDXX

Seilern Investment Management Ltd increased its stake in IDEXX Laboratories, Inc. by 20.7% in the second quarter, purchasing an additional 16,729 shares. The firm now holds 97,560 shares valued at approximately $51.4 million, making IDEXX its fifth-largest position. IDEXX Laboratories reported strong quarterly results, …

Addex Therapeutics (0QNV) Q1 2026 Earnings Report - Results, Call & Slides

California State Teachers Retirement System Boosts Position in Standex International Corporation $SXI

The California State Teachers Retirement System increased its stake in Standex International Corporation by 26.5% during the first quarter, bringing its total holdings to 14,604 shares valued at $3.72 million. Institutional investors collectively own 90.35% of the company, which recently exceeded earnings expectations with …

Celldex Therapeutics (CLDX) Stock Looks Rich On Book Value But Strong On Returns

IDEXX Laboratories Inc (HAM:IX1) Stock Price & 30 Year Financial Data

This article provides comprehensive 30-year financial data for IDEXX Laboratories Inc (HAM:IX1), including growth rates for revenue, EPS, EBIT, EBITDA, and free cash flow. It details key financial metrics such as Market Cap, Enterprise Value, PE Ratio, PB Ratio, and GF Score, offering an …

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock's …

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operations increased to US$0.94. Over the first half of 2026, revenue slipped to just US$0.037 million as …

Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises …